B cell responses to HIV and the development of human monoclonal antibodies
- 1 May 1992
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 88 (2) , 189-202
- https://doi.org/10.1111/j.1365-2249.1992.tb03061.x
Abstract
SUMMARY: In this review B cell responses in HIV-infected individuals are summarized together with the techniques used to date to produce human monoclonals to HIV and the properties of these antibodies. Profound disturbances in B cell responses are apparent both in vivo and in vitro. While there is evidence in vivo of marked polyclonal B cell activation, primary and secondary antibody responses are impaired. Similarly these cells exhibit spontaneous immunoglobulin secretion upon in vitro culture but do not readily respond to B cell mitogens and recall antigens including HIV. Furthermore, certain of these defects can be reproduced in normal B cells in vitro by incubation with HIV or HIV coded peptides. Individuals infected with HIV develop antibodies to HIV structural proteins (e.g. p17, p24, gp41 and gp120) and regulatory proteins (e.g. vif, nef, RT). Autoantibodies against a number of immunologically important molecules are also frequently observed. The anti-HIV antibodies are predominantly of the IgG1 isotype and exhibit a variety of effects on the virus in vitro. To date, using conventional immortalization strategies, an appreciable number of human monoclonals to HIV have been developed. These have been specific for gp41, gp120 and gag with antibodies of the former specificity predominating. The majority of these antibodies have been of the IgGl isotype. Only a small number of the antibodies neutralize virus in vitro and most of these react with gp120. The neutralizing antibodies recognize conformational and carbohydrate epitopes or epitopes in amino acid positions 306–322. The predominant epitopes recognized by the anti-gp41 antibodies were in amino acid positions 579–620 and 644–662. A high percentage (≏ 25%) of these antibodies enhance viral growth in vitro. The problems relating to the production of human monoclonals to HIV are discussed together with strategies that could be used in the future.Keywords
This publication has 209 references indexed in Scilit:
- An inhibition enzyme immunoassay using a human monoclonal antibody (K14) reactive with gp41 of HIV-1 for the serology of HIV-1 infectionsAIDS, 1991
- Epitopes of human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins recognized by antibodies in the sera of HIV-1-infected individualsClinical Immunology and Immunopathology, 1991
- IgG subclass responses to human immunodeficiency virus-1 antigens: Lack of IgG2 response to gp41 correlates with clinical manifestation of diseaseClinical Immunology and Immunopathology, 1991
- Isotype, distribution and target analysis of lymphocyte reactive antibodies in patients with human immunodeficiency virus infectionClinical Immunology and Immunopathology, 1989
- A hybridoma producing human monoclonal antibody specific for glycoprotein 120kDa of human immunodeficiency virus (HIV-1)Life Sciences, 1989
- Human monoclonal antibody against glycoproteins of human immunodeficiency virusBiochemical and Biophysical Research Communications, 1988
- Spontaneous in vitro production of virus-specific antibody by lymphocytes from HIV-infected subjectsClinical Immunology and Immunopathology, 1988
- Antilymphocyte Antibodies and Seropositivity for Retroviruses in Groups at High Risk for AIDSNew England Journal of Medicine, 1985
- Do natural killer cells regulate B-cell activity?Immunology Today, 1984
- Abnormalities of B-Cell Activation and Immunoregulation in Patients with the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1983